Physician profile
Robert John Struthers
NPI 1982738795
$2,403.89
in general payments reported to CMS, 2019-2025
39 companies · $671 in 2025
The $671 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $337 · 2020: $101 · 2021: $183 · 2022: $354 · 2023: $325 · 2024: $433 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,393 · Education: $35.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,393.25 |
| Education | $35.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $576.34 | 2024-2025 | |
| Itamar Medical INC | $177.90 | 2022-2023 | Watchpatone |
| Inspire Medical Systems, INC. | $163.24 | 2022-2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $127.62 | 2019-2025 | |
| Abbvie INC. | $100.39 | 2021-2025 | |
| Abbott Laboratories | $88.30 | 2023-2024 | Jot Dx, Infinity |
| Biogen, INC. | $83.58 | 2019-2024 | Tysabri, Vumerity |
| Philips North America LLC | $68.68 | 2021-2023 | |
| Lundbeck LLC | $63.17 | 2019-2025 | Vyepti |
| Emd Serono, INC. | $61.81 | 2019-2024 | |
| Resmed Corp | $61.46 | 2019-2023 | |
| Mdd US Operations, LLC | $56.70 | 2019-2024 | Gocovri |
| Janssen Pharmaceuticals, INC | $53.40 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $52.59 | 2023-2025 | Dysport |
| Livanova USA, INC. | $52.11 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $50.58 | 2019-2024 | Uplizna |
| Eisai INC. | $49.83 | 2019-2023 | |
| Genentech USA, INC. | $47.01 | 2021-2023 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $39.54 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $35.61 | 2024 | |
| Axsome Therapeutics, INC. | $29.68 | 2023-2025 | Sunosi |
| Argenx US, INC. | $28.95 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Medtronic, INC. | $28.68 | 2022 | |
| Allergan, INC. | $25.54 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $24.71 | 2025 | Lumryz |
| Janssen Biotech, INC. | $24.50 | 2025 | |
| Kyowa Kirin, INC. | $23.59 | 2020 | |
| Sunovion Pharmaceuticals INC. | $23.04 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.70 | 2021 | |
| 3b Medical, INC. | $20.73 | 2025 | Luna |
| Biomarin Pharmaceutical INC. | $19.37 | 2019 | |
| Genzyme Corporation | $18.52 | 2019 | |
| Avion Pharmaceuticals | $17.83 | 2022 | |
| Lilly USA, LLC | $16.31 | 2024 | Kisunla |
| Vanda Pharmaceuticals INC. | $14.88 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.81 | 2023 | Gammagard |
| Alnylam Pharmaceuticals INC. | $14.13 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.56 | 2020 | |
| Supernus Pharmaceuticals, INC. | $13.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Struthers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.